Xu Wenhao, Anwaier Aihetaimujiang, Liu Wangrui, Tian Xi, Su Jiaqi, Shi Guohai, Qu Yuanyuan, Zhang Hailiang, Ye Dingwei
Department of Urology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China.
Department of Interventional Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
J Natl Cancer Cent. 2022 Jul 13;2(3):162-170. doi: 10.1016/j.jncc.2022.07.001. eCollection 2022 Sep.
The genomic background affects the occurrence and metastasis of cancers, including clear cell renal cell carcinoma (ccRCC). However, reports focusing on the prognostic mutational signature of Chinese ccRCC are lacking.
Overall, 929 patients, including a training cohort with Chinese patients ( = 201), a testing cohort with Caucasian patients ( = 274), and a validation cohort ( = 454) were analyzed for the genomic landscape of ccRCC. Then, machine-learning algorithms were used to identify and evaluate the genomic mutational signature (GMS) in ccRCC. Analyses for prognosis, immune microenvironment, association with independent clinicopathological features, and predictive responses for immune checkpoint therapies (ICTs) were performed.
The DNA variation data of 929 patients with ccRCC suggested markedly differential genomic mutational frequency of the most frequent genes, such as , and between the Chinese and Caucasian populations. showed significant co-occurrence with and . We then successfully identified a seven-gene mutational signature (GMS) that included mutations in , and . The GMS significantly predicted progressive progression ( < 0.0001, HR = 2.81) and poor prognosis ( < 0.0001, HR = 3.89) in the Chinese training cohort. Moreover, ccRCC patients with the GMS had poor survival rates in the testing cohort ( = 0.020) and poor outcomes were predicted for those treated with ICTs in the validation cohort ( = 0.036). Interestingly, a favorable clinical response to ICTs, elevated expression of immune checkpoints, and increased abundance of tumor-infiltrated lymphocytes, specifically CD8 T cells, Tregs, and macrophages, were observed in the GMS cluster.
This study described the pro-tumorigenic GMS cluster that improved the prognostic accuracy in Chinese patients with ccRCC. Our discovery of the novel independent prognostic signature highlights the relationship between tumor phenotype and genomic mutational characteristics of ccRCC.
基因组背景影响包括透明细胞肾细胞癌(ccRCC)在内的癌症的发生和转移。然而,针对中国ccRCC预后突变特征的报道尚缺乏。
总共对929例患者进行了ccRCC基因组图谱分析,其中包括一个中国患者训练队列(n = 201)、一个白种人患者测试队列(n = 274)和一个验证队列(n = 454)。然后,使用机器学习算法识别和评估ccRCC中的基因组突变特征(GMS)。进行了预后分析、免疫微环境分析、与独立临床病理特征的关联分析以及免疫检查点疗法(ICTs)的预测反应分析。
929例ccRCC患者的DNA变异数据表明,中国人群和白种人群中最常见基因(如 、 和 )的基因组突变频率存在明显差异。 与 和 显示出显著的共现。然后,我们成功鉴定出一个七基因突变特征(GMS),其中包括 、 和 的突变。在中国训练队列中,GMS显著预测疾病进展(P < 0.0001,HR = 2.81)和预后不良(P < 0.0001,HR = 3.89)。此外,在测试队列中,具有GMS的ccRCC患者生存率较差(P = 0.020),在验证队列中,预测接受ICTs治疗的患者预后不良(P = 0.036)。有趣的是,在GMS簇中观察到对ICTs有良好的临床反应、免疫检查点表达升高以及肿瘤浸润淋巴细胞(特别是CD8 T细胞、调节性T细胞和巨噬细胞)丰度增加。
本研究描述了促肿瘤的GMS簇,其提高了中国ccRCC患者的预后准确性。我们发现的新型独立预后特征突出了ccRCC肿瘤表型与基因组突变特征之间的关系。